Abstracts - Orals, Poster Previews, and Posters
THR 099-112-Hyperandrogenic Ovarian Dysfunction and Female Reproductive Tract
Translational
Hall D-F, Reproductive Endocrinology (San Diego Convention Center)
Poster Board THR-105
Hui Peng1, Steven Soldin, PhD2, Mihriye Mete, PhD3, Suzette VanBuren Hayes4, John Maynard, MS5 and Vanita R Aroda6
1Georgetown University Hospital, DC, 2Georgetown University, Bethesda, MD, 3MedStar Health Research Institute, Hyattsville, MD, 4Medstar Health Research Institute, MD, 5Veralight, 6Medstar Health Research Institute, Hyattsville, MD
Background: Polycystic ovary syndrome (PCOS) is a common endocrine abnormality in women of reproductive age. Women with PCOS are at a higher risk of abnormal glucose tolerance and type 2 diabetes. Vitamin D insufficiency has been implicated in diabetes risk, potentially through effects on insulin secretion, insulin sensitivity, and systemic inflammation. Noninvasive assessment of dermal advanced glycation end products (AGEs) via skin fluorescence spectroscopy (SFS) measurements has been suggested for opportunistic type 2 diabetes screening.
Objective: To evaluate the relationship among glucose tolerance, sex steroid and vitamin D levels, and SFS in women with PCOS.
Methods: We enrolled 31 women with PCOS using the Rotterdam criteria. A total of 29 premenopausal control age- and BMI-matched women without PCOS were enrolled. Consented participants had 75 g OGTT, SCOUT DS® measurement of SFS, and serum simultaneously assayed for 13 steroid levels, including 25-OH-vitamin D levels, by isotope dilution liquid chromatography-tandem mass spectrometry.
Results: In the overall group (n=60), there was a significant though modest relationship between SFS scores and 2 hr post-challenge glucose levels (r=0.28, p=0.03). SFS scores also significantly correlated with serum triglyceride (r=0.29, p=0.03), DHEA (r=-0.41, p=0.002), deoxycortisol (r=-0.32, p=0.02), and 25-OH vitamin D (r=-0.34, p=0.01), with a trend for correlation with aldosterone (r=-0.21, p=0.11), corticosterone (r=-0.24, p=0.07), androstenedione (r=-0.23, p=0.09), and no significant relationship with DHEAS, testosterone, hydroxyprogesterone, estradiol, estrone, or estriol. In the PCOS group, there was a more pronounced relationship between SFS scores and deoxycortisol (r=-0.42, p=0.02), DHEA (r=-0.63, p=0.0003); 25-OH vitamin D (r=-.46, p=0.01).
Discussion/Conclusions: A positive relationship of SFS scores with glucose intolerance has previously been demonstrated (1). Further, low vitamin D levels have been implicated in risk of diabetes, as well as insulin resistance in PCOS. There are also reports suggesting a relationship between vitamin D level and AGEs: vitamin D reduces deposition of AGEs in the aortic wall and systemic oxidative stress in diabetic rats (2) and increases serum levels of the soluble receptor for advanced glycation end products in women with PCOS(3). Our report is the first to show a significant negative relationship between noninvasive assessment of AGEs via SFS and vitamin D levels. The relationship between SFS and vitamin D levels may simply reflect the relationship between vitamin D and glucose intolerance or perhaps contributions of the underlying PCOS pathophysiology, as AGEs have also been shown to be involved in the pathogenesis of PCOS(4).Further studies are required to delineate the causality and potential clinical implications of these associations.
1. Olson BP, et al. Noninvasive Skin Fluorescence Spectroscopy is Comparable to HbA1c and Fasting Plasma Glucose for Detection of Abnormal Glucose Tolerance. J of Diabetes Sci Technol. 2013; 7(4): 990-1000 2. Ekals S, et al. Vitamin D reduces deposition of advanced glycation end-products in the aortic wall and systemic oxidative stress in diabetic rats. Diabetes Res Clin Pract 2013; 100(2): 243-9. 3. Irani M, et al. Vitamin D increases serum levels of the soluble receptor for advanced glycation end products in women with PCOS. J Clin Endocrinol Metab 2014; 99(5): E886-90. 4. Merhi, Z. Advanced glycation end products and their relevance in female reproduction. Human Reproduction 2014; Vol.29, No.1 pp. 135–145
Disclosure: JM: former employee, VeraLight , Consultant, Miraculins . Nothing to Disclose: HP, SS, MM, SV, VRA
*Please take note of The Endocrine Society's News Embargo Policy at https://www.endocrine.org/news-room/endo-annual-meeting
Sources of Research Support: **This project has been funded in whole or in part with Federal funds (Grant # UL1TR000101 previously UL1RR031975) and (Grant # KL2TR000102 previously KL2RR031974) from National Center for Advancing Translational Sciences (NCATS) and National Center for Research Resources (NCRR), National Institutes of Health (NIH), through the Clinical and Translational Science Awards Program (CTSA), a trademark of DHHS, part of the Roadmap Initiative, “Re-Engineering the Clinical Research Enterprise.”